|
|
|
|
|
|
| Session Chair, Max Cummings, Johnson & Johnson |
|
Max Cummings is a Senior Scientist in the Molecular Design and Informatics group at Johnson & Johnson Pharmaceutical Research and Development where he is engaged in various aspects of structure-based drug discovery and design. In addition to supporting various medicinal chemistry projects, his ongoing research interests include protein-protein interactions and small molecule docking.
Max earned his B.Sc. in Chemistry from the University of Winnipeg (1985), M.Sc. in Chemistry from the University of Manitoba (1988) and Ph.D. in Biochemistry from the University of Alberta (1996). His undergraduate and M.Sc. research was in the area of mechanistic enzymology related to acetylcholinesterase. He worked in medicinal chemistry and enzymology at SynPhar Laboratories, Inc., Edmonton from 1988-1996, and in the Department of Biochemistry at the University of Alberta from 1992-1997. His Ph.D. research focused on biochemical applications of modeling and docking. In 1997 Dr.Cummings joined the computational chemistry group at SmithKlineBeecham, King of Prussia, and in 2000 moved to 3-Dimensional Pharmaceuticals, Exton, which later became part of Johnson & Johnson PRD.
|
| |
|
|
|
|
|
|
|
|
